# A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers

> **NCT02516774** · PHASE1 · WITHDRAWN · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris**

## Conditions studied

- Anaplastic Thyroid Cancers

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT02516774
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-12
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients enrolled
- **Last updated:** 2016-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02516774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02516774, "A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02516774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*